Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
Go back to Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1102.08 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1102.08 | 52 Week High | $88.16 | |||
| Open | $1102.08 | 52 Week Low | $67.88 | |||
| Day High | $1102.08 | P/E | 255.11 | |||
| Day Low | $1102.08 | EPS | $4.32 | |||
| Volume | 4,299 | |||||
